anti-GD2 chimeric antigen receptor T cells

Anti-GD2 chimeric antigen receptor (CAR) T cells are a type of adoptive cellular immunotherapy where a patient's T cells are genetically engineered to express a receptor targeting the disialoganglioside GD2. GD2 is a surface antigen highly expressed on neuroectodermal tumors, including neuroblastoma, melanoma, osteosarcoma, and certain high-grade gliomas, while having limited expression in normal tissues. The CAR construct typically comprises an extracellular single-chain variable fragment (scFv) derived from anti-GD2 antibodies (such as 14G2a or ch14.18), a transmembrane domain, and intracellular signaling domains including CD3-zeta and costimulatory molecules like 4-1BB (CD137) or CD28. Upon binding to GD2 on tumor cells, these CAR-T cells undergo activation, proliferation, and exert direct cytotoxic effects. Clinical development is primarily focused on pediatric solid tumors and refractory central nervous system malignancies, with ongoing research into modifications like GITRL co-expression to enhance persistence and overcome the immunosuppressive tumor microenvironment.

Other names

GD2-targeted CAR-T cellsGD-2-targeted CAR-T cellsGD 2-targeted CAR-T cellsanti-GD2 CAR-Tanti-GD-2 CAR-Tanti-GD 2 CAR-T